Research programme: anticancer small molecule therapeutics - Jnana Therapeutics
Latest Information Update: 03 Oct 2024
At a glance
- Originator Jnana Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphoric monoester hydrolase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 23 Sep 2024 Jnana Therapeutics has been acquired by Otsuka Pharmaceutical
- 31 Jul 2023 Early research in Cancer in USA (unspecified route) (Janana Therapeutics pipeline, July 2023)
- 12 May 2022 Jnana Therapeutics has patent pending for small molecule therapeutics in European Union, US, South Korea, China, Australia, Japan, Canada